This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Cybin Selects Numinus Wellness Inc.'s Cedar Clinical Research as clinical research site for Its Phase 3 Study of CYB003 CI
Transcript : Numinus Wellness Inc., Q2 2024 Earnings Call, Apr 15, 2024
Numinus Wellness Drops 25% as it Explores Options for its Canadian Operations; FQ2 Profit Falls MT
Toronto Stocks Edge Lower; Parkland Shares Up After Rebuffing Call for Strategic Review DJ
Numinus Wellness Exploring Options For Canadian Operations; Comes After It Posted QoQ Decrease in Q2 Revenue, Gross Profit MT
Numinus Wellness Brief: Co Has decided to Explore Opportunities to "Redefine, divest and/or discontinue" its Canadian clinical operations MT
Numinus Wellness Brief: Says To Focus on U.S. operations and Citing "Strategic Adjustments" in its Canadian Market Presence MT
Numinus Wellness Posts QoQ Decrease in Q2 Revenue, Gross Profit MT
An undisclosed buyer agreed to acquire Canadian clinical operations from Numinus Wellness Inc.. CI
Numinus Wellness Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
PharmAla Biotech Signs Sale Agreement with Numinus Wellness MT
Numinus Wellness Submits Clinical Trial Application to Health Canada MT
Numinus Wellness Brief: Says Submitted Clinical Trial Application MT
Numinus Wellness Inc. Submits Clinical Trial Application CI
Numinus Wellness Names Interim Chief Financial Officer MT
Numinus Wellness Inc. Announces Chief Financial Officer Changes CI
Numinus Wellness Inc. Announces Board Changes CI
Numinus Wellness Notes MindMed's "Positive" Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder MT
Numinus Wellness Closes $6 Million Bought Deal Public Offering MT
Numinus Wellness Corrects Its Own Statement Related To Holdings In Co-Investment Feeder Fund 3; Announced $6 Million Bought Deal Public Offering MT
Numinus Wellness Agrees to Sell Holdings in Alto Neuroscience MT
Transcript : Numinus Wellness Inc., Q1 2024 Earnings Call, Jan 15, 2024
Numinus Wellness Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Numinus Wellness Brief: Says Has initiated a review process to "Explore, review and evaluate a broad range of strategic alternatives" that may be available to it to unlock shareholder value MT
Chart Numinus Wellness Inc.
More charts
Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.08
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. NUMI Stock
  4. News Numinus Wellness Inc.
  5. Numinus Wellness : Announces up 11% as Health Canada Approves Open Label Study for MDMA-Assisted Therapy For PTSD